Hostname: page-component-77c89778f8-vsgnj Total loading time: 0 Render date: 2024-07-19T20:02:16.187Z Has data issue: false hasContentIssue false

Moratoria on the Use of Genetic Tests and Family History for Mortgage-Related Life Insurance

Published online by Cambridge University Press:  10 June 2011

A. S. Macdonald
Affiliation:
Department of Actuarial Mathematics and Statistics, Heriot-Watt University, Edinburgh EH14 4AS, U.K., Tel: +44(0)131-451-3209, Fax: +44(0)131-451-3249, Email: A.S.Macdonald@ma.hw.ac.uk

Abstract

The Human Genetics Commission intends to study the use of family history in underwriting, regarding it as genetic information in a broad sense. We survey the developments in genetics and insurance that led up to this decision. We propose a model for studying the possible costs of adverse selection in the mortgage-related life insurance market (which is important in the United Kingdom) with and without moratoria on the use of family history. We consider both level and decreasing term assurances, finding that the cost of adverse selection is slightly higher for the latter. Several assumptions about mutation penetrance, incidence of additional mortality, prevalence of genetic testing and insurance-buying behaviour are considered. Overall we conclude that: (a) a moratorium on genetic test results alone will lead to negligible adverse selection costs; while (b) a moratorium extended to family history will lead to premium increases just by redefining underwriting classes, with adverse selection being possible as well, but only in extreme circumstances would all premium increases be likely to exceed about 10%. However, we give examples in a model of a smaller life insurance market that show that our benign conclusions might not apply more generally.

Type
Sessional meetings: papers and abstracts of discussions
Copyright
Copyright © Institute and Faculty of Actuaries 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Association of British Insurers (1999). Genetic testing: ABI code of practice (revised August 1999). Association of British Insurers, London.Google Scholar
Campion, D., Dumanchin, C., Hannequin, D., Dubois, B., Belliard, S., Puel, M., Thomas-Anterion, C., Michon, A., Martin, C., Charbonnier, F., Raux, G., Camuzat, A., Penet, C., Mesnage, V., Martinez, M., Clerget-Darpoux, F., Brice, A. & Frebourg, T. (1999). Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. American Journal of Human Genetics, 65, 664670.CrossRefGoogle ScholarPubMed
Conte, S.D. & de Boor, C. (1972). Elementary numerical analysis. McGraw-Hill, New York.Google Scholar
House of Commons Science and Technology Committee (2001). Fifth report: Genetics and insurance. http://www.publications.parliament.uk/pa/cm200001/cmselect/cmsctech/174/17402.htmGoogle Scholar
Human Genetics Advisory Commission (1997). The implications of genetic testing for insurance. Human Genetics Advisory Commission, London.Google Scholar
Human Genetics Commission (2001). The use of genetic information in insurance: Interim recommendations of the Human Genetics Commission. http://www.hgc.gov.uk/business/_publications/_statement/_01may.htmGoogle Scholar
Macdonald, A.S. (1997). How will improved forecasts of individual lifetimes affect underwriting?. Philosophical Transactions of the Royal Society B, 352, 10671075, and (with discussion) British Actuarial Journal, 3, 1009–1025 and 1044–1058.CrossRefGoogle ScholarPubMed
Macdonald, A.S. (1999). Modeling the impact of genetics on insurance. North American Actuarial Journal, 3:1, 83101.CrossRefGoogle Scholar
Macdonald, A.S. & Pritchard, D.J. (2000). A mathematical model of Alzheimer's disease and the ApoE gene. ASTIN Bulletin, 30, 69110.CrossRefGoogle Scholar
Macdonald, A.S., Waters, H.R. & Wekwete, C.T. (2003). The genetics of breast and ovarian cancer I: a model of family history. Scandinavian Actuarial Journal, 2003, 127.CrossRefGoogle Scholar
Meiser, B. & Dunn, S. (2000). Psychological impact of genetic testing for Huntington's disease: an update of the literature. J. Neurol. Neurosurg. Psychiatry, 69, 574578.CrossRefGoogle ScholarPubMed
Pasternak, J.J. (1999). An introduction to human molecular genetics. Fitzgerald Science Press, Bethesda, Maryland.Google Scholar
Pritchard, D.J. (1997). Life assurance: financial implications of a change in insuring behaviour resulting from individuals' increased knowledge of their genetic predispositions. MSc dissertation, Heriot-Watt University, Edinburgh.Google Scholar
Subramanian, K., Lemaire, J., Hershey, J.C., Pauly, M.V., Armstrong, K. & Asch, D.A. (2000). Estimating adverse selection costs from genetic testing for breast and ovarian cancer: the case of life insurance. Journal of Risk and Insurance, 66, 531550.CrossRefGoogle Scholar
Yang, S. (2000). Some investigations into the rate at which life insurance is purchased in the U.K. MSc dissertation, Heriot-Watt University, Edinburgh.Google Scholar
Zimmern, R. (2001). What is genetic information? Genetics LawMonitor, 1:5, 913.Google Scholar